+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

PT Kimia Farma Tbk (KAEF) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • July 2026
  • GlobalData
  • ID: 2557189
PT Kimia Farma Tbk (KAEF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

PT Kimia Farma Tbk (Kimia Farma), a subsidiary of PT Bio Farma, is a pharmaceutical company that manufactures, commercializes, and distributes pharmaceutical products. The company's products include finished drugs, herbal medicines, and cosmetics. It offers products in various categories, including the alimentary system, allergy and immune system, anaesthetics (both local and general), antibiotics, antidotes, and detoxifying agents. Additional categories include cardiovascular and hematopoietic, dermatological, eye and ear, genito-urinary system, hormones, intravenous and other sterile products, metabolism, neuromuscular treatments, other chemotherapeutics, respiratory aids, vitamins, and minerals. Kimia Farma operates a distribution network that supplies its products to pharmacies, hospitals, and medical centers in Asia, Europe, and Africa. The company operates manufacturing plants in Jakarta, Bandung, Semarang, Watudakon, Medan, and West Java, among others. Kimia Farma is headquartered in Jakarta, Indonesia.

PT Kimia Farma Tbk Key Recent Developments

  • Apr 06, 2026: PT Kimia Farma Launches Stemxera and Expands Biotechnology Collaboration
  • Dec 30, 2025: EGMS Approves Transfer of PT Kimia Farma Tbk Assets
  • Oct 16, 2025: PT Kimia Farma Tbk is Collaborating on Export Distribution with Soidal Medical Supplies Ltd Papua New Guinea
  • Oct 13, 2025: KIMIA FARMA, in Collaboration with RSCM, Expands Stem Cell Therapy Services

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Biocon Ltd - Key Facts
  • Biocon Ltd - Key Employees
  • Biocon Ltd - Key Employee Biographies
  • Biocon Ltd - Major Products and Services
  • Biocon Ltd - History
  • Biocon Ltd - Company Statement
  • Biocon Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Biocon Ltd - Business Description
  • Business Segment: Biosimilars
  • Overview
  • Performance
  • Business Segment: Generics
  • Overview
  • Performance
  • Business Segment: Research Services
  • Overview
  • Performance
  • Geographical Segment: European Union (including Ireland)
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: United States of America
  • Performance
  • R&D Overview
  • Biocon Ltd - Corporate Strategy
  • Biocon Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Biocon Ltd - Strengths
  • Biocon Ltd - Weaknesses
  • Biocon Ltd - Opportunities
  • Biocon Ltd - Threats
  • Biocon Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Biocon Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 29, 2026: Biocon Receives Health Canada Approval for Yesintek® (ustekinumab) Autoinjector Pen
  • Jul 28, 2026: Biocon Foundation and IISc Convene National Experts to Shape India’s Oral Cancer Elimination Strategy
  • Jul 21, 2026: Biocon Limited partners with Tabuk Pharmaceuticals to commercialise its Glucagon-like peptide-1 (GLP-1) products in the Middle East region
  • Jul 21, 2026: Biocon Announces Mr. Bobby Kanubhai Parikh Has Completed Independent Director and Consequently Ceased to Be a Director of the Company
  • Jun 24, 2026: Biocon Reinforces Commitment to Diabetes Care in Malaysia as Duopharma Biotech Secures Insulin Tenders
  • May 07, 2026: Biocon Reports Q4 FY26 Total Income and EBITDA, and FY26 Financial Results
  • Apr 30, 2026: U.S. FDA Completes Pre-License Inspection at Biocon’s Biosimilars Site at Biocon Park, Bengaluru, India
  • Apr 28, 2026: Toyota Mobility Foundation, Biocon, and WRI India Launch Commute Nudge Program to Promote Public Transport
  • Apr 22, 2026: Health Canada approves Biocon’s two denosumab biosimilars
  • Mar 27, 2026: Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Biocon Ltd, Key Facts
  • Biocon Ltd, Key Employees
  • Biocon Ltd, Key Employee Biographies
  • Biocon Ltd, Major Products and Services
  • Biocon Ltd, History
  • Biocon Ltd, Other Locations
  • Biocon Ltd, Subsidiaries
  • Biocon Ltd, Joint Venture
  • Biocon Ltd, Key Competitors
  • Biocon Ltd, Ratios based on current share price
  • Biocon Ltd, Annual Ratios
  • Biocon Ltd, Interim Ratios
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Biocon Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Biocon Ltd, Performance Chart (2022 - 2026)
  • Biocon Ltd, Ratio Charts
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026